DiaMedica Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 13, 2019 and accepted by EDGAR at Nov 13, 2019, 16:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-07-01 to 2019-09-30 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $6.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$8.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $12.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $29.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$2.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$8.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$0.68 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$7.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-09-30 | $4.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $10.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $11.0m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $1.2m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2019-09-30 | $9.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-19-022682. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.